EU OKs Extended Indication for Amgen’s Myeloma Drug Kyprolis
Global biotech firm Amgen has announced that the European Commission…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Multiple Myeloma Treatment Outcomes May Improve with ‘Next-Generation Drug Candidates’, Review Says
Advances in the molecular understanding of multiple myeloma (MM)…
One Multiple Myeloma Induction Therapy Stands Out in Test for Transplant-eligible Patients
Results from a clinical trial support the use of…
Relapsed/Refractory Multiple Myeloma Drug by Takeda Receives Negative Opinion from EMA
Takeda Pharmaceutical Company Limited has recently received a negative…
Multiple Myeloma Among Topics in APSHO Educational Series for Healthcare Workers
The Advanced Practitioners Society for Hematology and Oncology…
New Data from Key Trial of Kyprolis to Treat Advanced Multiple Myeloma Shows Benefits
Amgen reported findings from a post-hoc analysis of the pivotal Phase…
